Clinical trial
Compassionate Use Trial for Unresectable Melanoma With Ipilimumab
NCT00495066 · Bristol-Myers Squibb, Industry · No longer available
Key facts
| NCT number | NCT00495066 |
|---|---|
| Title | Compassionate Use Trial for Unresectable Melanoma With Ipilimumab |
| Official title | A Multicenter Treatment Protocol for Expanded Access Use of Ipilimumab (BMS-734016) Monotherapy in Subjects With Unresectable Stage III or Stage IV Melanoma |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | No longer available |
| Study type | Expanded Access |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | Ipilimumab |
| First posted | Jul 2, 2007 |
| Last update posted | Jun 3, 2013 |
| Countries | Brazil |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: